Semaglutide Therapy

Semaglutide mimics the action of GLP-1, an incretin hormone naturally produced in the gut after eating, but with modifications that dramatically extend its half-life to approximately one week. It acts on GLP-1 receptors in multiple organs: in the pancreas, it enhances glucose-dependent insulin secretion; in the brain, it acts on hypothalamic appetite centers to reduce hunger and increase satiety; and in the stomach, it slows gastric emptying, prolonging the feeling of fullness after meals. The combined effect of central appetite suppression, improved metabolic signaling, and delayed gastric transit produces the significant caloric reduction and metabolic improvements observed in clinical trials.

Semaglutide is sought by individuals struggling with weight management who have not achieved their goals through diet and exercise alone. Patients with metabolic health concerns, including those with elevated glucose levels and cardiovascular risk factors, are frequently recommended this peptide by their providers. It is also sought by individuals looking for a structured, medically supervised approach to sustainable weight loss.

Injectable semaglutide is typically administered once weekly via subcutaneous injection in the abdomen, thigh, or upper arm. Treatment begins with a low dose that is gradually titrated upward over several weeks to minimize gastrointestinal side effects. An oral formulation is also available for daily use. Most protocols involve ongoing use with regular medical monitoring.